Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$12.08 +0.6%	$9.39	$6.42 ▼ $12.53	$1.58B	1.23	2.80 million shs	1.00 million shs
CDTX Cidara Therapeutics	$67.49 +3.8%	$52.82	$10.14 ▼ $69.36	$1.65B	1.18	425,657 shs	661,938 shs
IMCR Immunocore	$32.67 +0.6%	$33.33	$23.15 ▼ $39.33	$1.64B	0.77	315,491 shs	382,254 shs
REPL Replimune Group	$5.60 +6.7%	$7.87	$2.68 ▼ $17.00	$409.79M	0.67	17.99 million shs	2.70 million shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	-0.17%	0.00%	+39.33%	+45.22%	+86.78%
CDTX Cidara Therapeutics	+5.76%	+2.81%	+13.99%	+153.04%	+402.16%
IMCR Immunocore	+0.46%	-1.55%	-12.02%	+4.10%	-12.43%
REPL Replimune Group	-0.57%	+3.04%	-57.39%	-40.07%	-50.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	2.9781 of 5 stars	1.5	3.0	0.0	3.4	2.5	3.1
CDTX Cidara Therapeutics	3.5373 of 5 stars	2.6	3.0	4.6	2.2	1.7	0.0
IMCR Immunocore	1.9622 of 5 stars	3.3	1.0	0.0	2.8	2.5	0.0
REPL Replimune Group	4.4707 of 5 stars	4.2	2.0	4.5	2.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	3.00	Buy	$12.00	-0.66% Downside
CDTX Cidara Therapeutics	3.11	Buy	$64.14	-4.96% Downside
IMCR Immunocore	2.50	Moderate Buy	$58.00	77.53% Upside
REPL Replimune Group	2.33	Hold	$7.67	36.90% Upside

Current Analyst Ratings Breakdown

Latest REPL, IMCR, AUPH, and CDTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$59.00 ➝ $66.00
8/8/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $74.00
8/8/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $74.00
8/1/2025	AUPH Aurinia Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $9.00
7/30/2025	AUPH Aurinia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$17.00
7/30/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
7/23/2025	REPL Replimune Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$17.00 ➝ $3.00
7/23/2025	REPL Replimune Group	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Underperform	$27.00 ➝ $2.00
7/23/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/22/2025	REPL Replimune Group	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$235.13M	6.76	$0.31 per share	39.01	$2.55 per share	4.74
CDTX Cidara Therapeutics	$1.27M	1,347.67	N/A	N/A	$19.76 per share	3.42
IMCR Immunocore	$310.20M	5.31	N/A	N/A	$7.71 per share	4.24
REPL Replimune Group	N/A	N/A	N/A	N/A	$4.31 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	$5.75M	$0.43	28.09	21.57	N/A	23.31%	20.06%	13.81%	11/6/2025 (Estimated)
CDTX Cidara Therapeutics	-$169.83M	-$11.13	N/A	N/A	N/A	N/A	-50.81%	-42.46%	11/6/2025 (Estimated)
IMCR Immunocore	-$51.09M	-$0.40	N/A	N/A	N/A	-5.70%	-5.40%	-1.93%	11/5/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.24	N/A	N/A	N/A	N/A	-69.34%	-52.81%	N/A

Latest REPL, IMCR, AUPH, and CDTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CDTX Cidara Therapeutics	-$1.87	-$1.65	+$0.22	-$1.65	N/A	N/A
8/7/2025	Q2 2025	IMCR Immunocore	-$0.21	-$0.20	+$0.01	-$0.20	$122.96 million	$130.65 million
8/7/2025	Q1 2026	REPL Replimune Group	-$0.83	-$0.95	-$0.12	-$0.95	$0.50 million	N/A
7/31/2025	Q2 2025	AUPH Aurinia Pharmaceuticals	$0.17	$0.16	-$0.01	$0.16	$64.27 million	$70.01 million
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.18	5.23	4.63
CDTX Cidara Therapeutics	N/A	16.45	16.45
IMCR Immunocore	1.01	5.89	5.86
REPL Replimune Group	0.21	6.94	6.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
CDTX Cidara Therapeutics	35.82%
IMCR Immunocore	84.50%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	12.20%
CDTX Cidara Therapeutics	3.89%
IMCR Immunocore	10.40%
REPL Replimune Group	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	131.63 million	115.57 million	Optionable
CDTX Cidara Therapeutics	90	25.36 million	24.37 million	No Data
IMCR Immunocore	320	50.39 million	45.15 million	Optionable
REPL Replimune Group	210	78.06 million	74.00 million	Optionable

REPL, IMCR, AUPH, and CDTX Headlines

Recent News About These Companies

REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 21 at 4:00 PM | globenewswire.com

Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – Contact The Gross Law Firm

August 21 at 3:27 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

August 21 at 11:33 AM | globenewswire.com

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

August 21 at 11:10 AM | prnewswire.com

FDA ‘uncertainty’ forces Krystal Biotech to shutter cancer drug trial

August 21 at 9:11 AM | statnews.comS

Replimune Group, Inc. (REPL) Investors: September 22, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

August 20 at 11:09 PM | theglobeandmail.com

Investors in Replimune Group, Inc. (REPL): Protect Your Rights - Contact Levi & Korsinsky Before September 22, 2025

August 20 at 11:09 PM | theglobeandmail.com

Investors Who Lost Money on Replimune Group, Inc. (REPL) Should Contact Levi & Korsinsky About Pending Class Action - REPL

August 20 at 6:09 PM | theglobeandmail.com

REPL Investors Have the Opportunity to Lead the Replimune Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

August 20 at 3:43 PM | globenewswire.com

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug – Hagens Berman

August 20 at 1:16 PM | globenewswire.com

Shareholders of Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPL

August 19 at 4:14 PM | globenewswire.com

Class Action Filed Against Replimune Group, Inc. ...

August 19 at 9:31 AM | gurufocus.com

Class Action Filed Against Replimune Group, Inc. (REPL) - September 22, 2025 Deadline to Join - Contact Levi & Korsinsky

August 19 at 8:45 AM | prnewswire.com

Replimune Group, Inc. (NASDAQ:REPL) Receives $7.67 Average Target Price from Analysts

August 19 at 2:23 AM | americanbankingnews.com

Replimune Group, Inc. Class Action: The Gross Law Firm Reminds Replimune Group, Inc. ...

August 18 at 5:31 PM | gurufocus.com

Replimune Group, Inc. Class Action: The Gross Law Firm Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 – REPL

August 18 at 4:04 PM | globenewswire.com

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug – Hagens Berman

August 18 at 12:17 PM | globenewswire.com

Contact The Gross Law Firm by September 22, 2025 Deadline to Join Class Action Against Replimune Group, Inc.(REPL)

August 18 at 8:45 AM | prnewswire.com

Short Interest in Replimune Group, Inc. (NASDAQ:REPL) Increases By 165.7%

August 18 at 5:32 AM | marketbeat.com

REPL Investors Have Opportunity to Lead Replimune Group, Inc. ...

August 18 at 3:30 AM | gurufocus.com

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm

August 18 at 2:53 AM | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

REPL, IMCR, AUPH, and CDTX Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$12.08 +0.07 (+0.58%)

Closing price 04:00 PM Eastern

Extended Trading

$12.04 -0.04 (-0.29%)

As of 07:43 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Cidara Therapeutics NASDAQ:CDTX

$67.49 +2.46 (+3.78%)

Closing price 04:00 PM Eastern

Extended Trading

$68.24 +0.75 (+1.11%)

As of 07:59 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Immunocore NASDAQ:IMCR

$32.67 +0.18 (+0.55%)

Closing price 04:00 PM Eastern

Extended Trading

$32.69 +0.02 (+0.06%)

As of 04:10 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Replimune Group NASDAQ:REPL

$5.60 +0.35 (+6.67%)

Closing price 04:00 PM Eastern

Extended Trading

$5.50 -0.10 (-1.79%)

As of 07:38 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time